BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37459273)

  • 1. Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort.
    Nguyen Y; Blanchet B; Urowitz MB; Hanly JG; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Clarke AE; Bernatsky S; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; Alarcón GS; Van Vollenhoven RF; Aranow C; Le Guern V; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; Kalunian KC; Jacobsen S; Peschken CA; Kamen DL; Askanase A; Buyon J; Costedoat-Chalumeau N
    Arthritis Rheumatol; 2023 Dec; 75(12):2195-2206. PubMed ID: 37459273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
    Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.
    Fessler BJ; Alarcón GS; McGwin G; Roseman J; Bastian HM; Friedman AW; Baethge BA; Vilá L; Reveille JD;
    Arthritis Rheum; 2005 May; 52(5):1473-80. PubMed ID: 15880829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
    Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.
    Legge A; Kirkland S; Rockwood K; Andreou P; Bae SC; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin PR; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
    Arthritis Rheumatol; 2020 Apr; 72(4):658-666. PubMed ID: 31631584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus.
    Feldman CH; Collins J; Zhang Z; Subramanian SV; Solomon DH; Kawachi I; Costenbader KH
    Semin Arthritis Rheum; 2018 Oct; 48(2):205-213. PubMed ID: 29458974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
    Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
    Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
    Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).
    Ugarte-Gil MF; Wojdyla D; Pons-Estel GJ; Catoggio LJ; Drenkard C; Sarano J; Berbotto GA; Borba EF; Sato EI; Tavares Brenol JC; Uribe O; Ramirez Gómez LA; Guibert-Toledano M; Massardo L; Cardiel MH; Silveira LH; Chacón-Diaz R; Alarcón GS; Pons-Estel BA;
    Ann Rheum Dis; 2017 Dec; 76(12):2071-2074. PubMed ID: 28939626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
    Garg S; Unnithan R; Hansen KE; Costedoat-Chalumeau N; Bartels CM
    Arthritis Care Res (Hoboken); 2021 May; 73(5):707-716. PubMed ID: 32004406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
    Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri MA; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim SS; van Vollenhoven R; Nived O; Jönsen A; Kamen DL; Aranow C; Sánchez-Guerrero J; Gladman DD; Fortin PR; Alarcon GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase AD; Khamashta M; Bruce IN; Inanc M; Lukusa L; Bernatsky S
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36396267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
    Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF; Hanly J; Urowitz M; Gordon C; Bae SC; Romero-Diaz J; Sanchez-Guerrero J; Bernatsky S; Clarke AE; Wallace DJ; Isenberg DA; Rahman A; Merrill JT; Fortin PR; Gladman DD; Bruce IN; Petri M; Ginzler EM; Dooley MA; Ramsey-Goldman R; Manzi S; Jönsen A; van Vollenhoven RF; Aranow C; Mackay M; Ruiz-Irastorza G; Lim S; Inanc M; Kalunian K; Jacobsen S; Peschken C; Kamen DL; Askanase A; Pons-Estel BA; Alarcón GS
    Ann Rheum Dis; 2022 Nov; 81(11):1541-1548. PubMed ID: 35944946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
    Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
    Feldman CH; Yazdany J; Guan H; Solomon DH; Costenbader KH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1712-21. PubMed ID: 26097166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
    Bruce IN; O'Keeffe AG; Farewell V; Hanly JG; Manzi S; Su L; Gladman DD; Bae SC; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Petri M; Steinsson K; Dooley MA; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Urowitz MB
    Ann Rheum Dis; 2015 Sep; 74(9):1706-13. PubMed ID: 24834926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.